Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MH004 cream in nonsegmental vitiligo
CTR20240183Phase 2Active
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tofacitinib etocomil in nonsegmental vitiligo, sponsored by Minghui Pharmaceutical, Inc.. Started Mar 2024; status: active.
02
Drugs
tofacitinib etocomil
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on CTR20240183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240183.